Based on the significant association between the two chemokine axes and HCC, we hypothesized that targeted therapies against CCL2/CCR2 and CXCLs/CXCR2 can improve the anti-tumor effect of TACE. The gene discussed is CCR2; the disease is hepatocellular carcinoma.